查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008494

胃麻痹治疗市场：2026-2032年全球市场预测（按产品类型、药物类别、给药途径、最终用户和分销管道划分）

Gastroparesis Drugs Market by Product Type, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，胃麻痹治疗市场价值将达到 48.7 亿美元，到 2026 年将成长至 52.4 亿美元，到 2032 年将达到 79.7 亿美元，复合年增长率为 7.27%。

主要市场统计数据
基准年 2025 48.7亿美元
预计年份：2026年 52.4亿美元
预测年份 2032 79.7亿美元
复合年增长率 (%) 7.27%

全面而权威地概述了胃麻痹症的临床复杂性、治疗限制和商业性考量，这些因素共同塑造了胃麻痹症的治疗模式。

胃麻痹的治疗具有持续的临床复杂性、未被满足的需求以及传统药物疗法与新兴药物疗法并存的特点。患者会出现多种症状，现有治疗方案难以有效管理，而临床医师必须在长期治疗过程中权衡疗效、安全性和耐受性。在此背景下，产业相关人员面临监管、成本压力以及证明病患报告结果（PRO）显着改善的挑战。

简要概述了重塑胃麻痹症治疗方法和商业化策略的突破性科学、监管和商业性变革。

近年来，由于药物研发的进步、监管机构对以患者为中心的终点指标的重视以及替代给药技术的成熟，胃麻痹领域发生了变革性的变化。製药创新者越来越重视针对特定路径以改善胃动力并减少全身副作用的分子。同时，口服生物製药製剂技术的成熟和经皮给药概念的出现，拓展了临床医生可用的药理学工具，使其能够提供超越单纯疗效声明的差异化价值提案。

分析性评论：2025 年美国关税上调将如何加剧胃麻痹药物整个供应链网路中的供应链、采购和定价趋势。

美国提高关税为全球药品供应链和筹资策略带来了新的复杂性，尤其是那些依赖进口活性成分（API）和最终製剂的药品。先前透过跨国采购API来优化成本的生产网络，必须重新评估供应商合格、缓衝库存政策以及近岸外包的可行性，以缓解关税造成的成本波动。同时，各公司正在审查与合约研发生产机构（CDMO）的合约条款，以分担或承担增加的成本负担，这反过来又影响了与经销商和下游支付方的价格谈判。

从多方面细分的观点揭示了产品类型、治疗领域、给药途径、分销管道和最终用户如何独特地影响临床引入和商业策略。

细分市场分析揭示了产品类型、药物类别、给药途径、分销管道和最终用户等方面的不同动态，这些因素共同影响着治疗方法的采纳和商业性执行。根据产品类型，市场可分为品牌药和学名药。品牌药通常基于目标临床数据和延长生命週期策略，而学名药优先考虑成本效益和提高处方笺采纳率。这些相互矛盾的趋势为生产者带来了不同的奖励。品牌药开发商优先考虑差异化和证据深度，而学名药生产商则专注于优化生产规模和分销管道。

一项策略性区域分析，旨在揭示美洲、欧洲、中东和非洲以及亚太地区的差异如何影响胃麻痹治疗的取得、监管和商业化。

区域趋势对整个胃麻痹治疗领域的进入途径、监管预期和商业模式都具有显着影响。在美洲，奖励激励机制、严格的支付方审查以及多样化的报销环境并存，这促使企业需要製定差异化的打入市场策略和价值论证。此外，美洲各地临床实践的差异会影响处方集选择以及新药和成熟药物的相对采用率，而供应链的韧性仍然是营运中的重中之重。

这份公司简介深入分析了创新、合作和营运韧性如何重新定义胃麻痹治疗研发公司的竞争策略。

胃麻痹领域的企业层面措施体现了创新、生命週期管理和营运效率之间的平衡。原厂药公司持续投资于标靶机制，以期提高疗效和耐受性，并经常将临床开发与生物标记策略和患者报告结局指标相结合，以展现差异化价值。同时，专科药和学名药生产商则利用成本和供应优势，抢占现有产品仍被临床接受的细分市场。

为行业领导者提供切实可行的、高优先级的建议，以加强证据生成、供应韧性和基于价值的胃麻痹治疗应用。

在胃麻痹症治疗领域寻求竞争优势的领导者应优先考虑以患者为中心的疗效指标和基于实证医学的框架，以证明其在真实临床实践中的疗效。早期投资于病患报告结局指标、长期安全性登记和可操作的试验设计，能够增强对支付方和医疗服务提供者的价值提案，并有助于将该疗法与现有治疗方法分开来。与临床医生和患者权益倡导网络进行策略合作，可以加速有意义终点的选择和应用，同时加强上市后数据的收集。

一份透明且严谨的调查方法总结，解释了我们如何透过对主要调查和有针对性的主要访谈进行三角验证，为利害关係人产生检验的见解。

本分析的调查方法结合了系统性的二手资料研究和有针对性的原始资料收集，以确保证据的广度和深度。二级资讯来源包括同行评审的临床文献、监管指导文件和公开的企业披露信息，这些资料被整合起来，用于梳理治疗机制、安全性概况和监管先例。为了补充这一基础，研究人员还对临床专家、供应链高管和医保报销系统专家进行了访谈，以即时了解观点对准入障碍、处方行为和采购趋势的看法。

明确且具有策略意义的结论，整合了临床潜力、商业性需求和营运弹性，这对于成功实施胃麻痹治疗方案至关重要。

简而言之，胃麻痹的治疗格局正处于一个转折点，科学进步、政策转变和实际情况在此交汇，重新定义价值创造。标靶药理学和给药技术的进步为改善患者预后带来了巨大潜力，但这些技术能否在临床实践中得到应用，取决于是否有令人信服的证据、与支付方的合作以及能够满足门诊和居家照护需求的实用给药模式。同时，关税和供应链脆弱性等宏观层面的压力凸显了韧性和策略采购在维持患者用药可及性和商业性永续性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：胃麻痹治疗市场：依产品类型划分

  • 品牌商品
  • 学名药

第九章：胃麻痹治疗药物市场：依药物类别划分

  • 多巴胺拮抗剂
    • 西沙必利
    • 多姆哌立登
    • 甲氧氯普胺
  • 胃动素受体促效剂
    • 阿奇霉素
    • 红霉素
  • 血清素受体促效剂
    • Granisetron
    • Ondansetron

第十章：胃麻痹治疗药物市场：依给药途径划分

  • 注射药物
  • 口服
  • 经皮吸收

第十一章：胃麻痹治疗药物市场：依最终用户划分

  • 诊所
  • 居家照护设施
  • 医院

第十二章：胃麻痹治疗药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：胃麻痹治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：胃麻痹治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：胃麻痹治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国胃麻痹治疗药物市场

第十七章：中国胃麻痹治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market was valued at USD 4.87 billion in 2025 and is projected to grow to USD 5.24 billion in 2026, with a CAGR of 7.27%, reaching USD 7.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.87 billion
Estimated Year [2026] USD 5.24 billion
Forecast Year [2032] USD 7.97 billion
CAGR (%) 7.27%

A precise and authoritative introduction framing clinical complexity, treatment limitations, and commercial considerations shaping the gastroparesis therapeutic landscape

The therapeutic arena for gastroparesis is characterized by persistent clinical complexity, unmet patient needs, and a mix of legacy and evolving pharmacologic approaches. Patients experience a broad spectrum of symptoms that can be difficult to manage with existing options, while clinicians balance efficacy, safety, and tolerability in long-term care pathways. Against this backdrop, industry players are navigating regulatory scrutiny, cost pressures, and the imperative to demonstrate meaningful improvements in patient-reported outcomes.

This report provides a concise orientation to the clinical and commercial context shaping gastroparesis drugs. It examines drug class dynamics, delivery modalities, distribution pathways, and end-user considerations that influence adoption in inpatient, clinic, and home care settings. By integrating recent clinical evidence with supply chain and policy developments, the introduction sets the stage for deeper analyses that follow, enabling leaders to contextualize tactical choices within a broader therapeutic and operational framework.

A concise synthesis of the transformative scientific, regulatory, and commercial shifts reshaping gastroparesis therapeutics and commercialization strategies

Recent years have seen transformative shifts in the gastroparesis landscape driven by advances in drug development, regulatory focus on patient-centered endpoints, and the maturation of alternative delivery technologies. Pharmaceutical innovators are increasingly prioritizing molecules that target specific mechanistic pathways to improve gastric motility while mitigating systemic adverse effects. Concurrently, the maturation of oral-biologic formulation techniques and transdermal delivery concepts has broadened the pharmacologic toolkit available to clinicians, enabling differentiated value propositions beyond simple efficacy claims.

Commercially, the industry is experiencing strategic convergence between specialty developers, contract manufacturers, and generic producers. This has accelerated lifecycle management strategies for established agents through reformulation and new routes of administration that extend clinical utility. At the same time, payers and providers are shifting toward value-based contracting and outcome-aligned reimbursement, raising the bar for evidence generation and long-term safety monitoring. These combined forces are reshaping market entry strategies, clinical trial design, and commercialization pathways, and they will continue to influence investment priorities and partnership models across the sector.

An analytical review of how elevated U.S. tariffs in 2025 have amplified supply chain, procurement, and pricing dynamics across gastroparesis drug supply networks

The imposition of elevated tariffs in the United States has introduced a conditional layer of complexity into global pharmaceutical supply chains and procurement strategies, particularly for agents reliant on imported active pharmaceutical ingredients and finished dosage forms. Manufacturing networks that previously optimized cost through cross-border API sourcing must now re-evaluate supplier qualification, buffer inventory policies, and nearshoring feasibility to mitigate tariff-driven cost volatility. In parallel, firms are recalibrating contractual terms with contract development and manufacturing organizations to share or absorb incremental cost burdens, which in turn affects pricing negotiations with distributors and downstream payers.

Operationally, increased import levies have prompted a reassessment of inventory strategies for hospital pharmacies, specialty distributors, and retail channels, with many organizations extending lead times and diversifying supplier bases to protect continuity of supply. Clinicians and procurement officers may experience short-term pricing pressure that influences prescribing patterns, particularly where multiple therapeutic alternatives exist. Furthermore, tariff-driven cost increases can constrain manufacturers' flexibility to finance late-stage clinical programs or reformulation initiatives, as capital is reallocated toward ensuring uninterrupted production and compliance. Ultimately, the cumulative impact emphasizes resilience-building measures-regional manufacturing investments, strategic API stockpiles, and tightened quality oversight-to maintain product availability and preserve patient access in an increasingly protectionist trade environment.

A multi-dimensional segmentation lens revealing how product types, therapeutic classes, delivery routes, channels, and end users uniquely influence clinical adoption and commercial strategy

Segmentation analysis reveals differentiated dynamics across product type, drug class, route of administration, distribution channel, and end user that collectively shape therapeutic adoption and commercial execution. Based on Product Type, the landscape distinguishes branded therapies from generics, with branded agents typically anchored by targeted clinical data and lifecycle-extension strategies while generics emphasize cost-efficiency and formulary penetration. These opposing dynamics create distinct incentives for manufacturers: branded developers prioritize differentiation and evidence depth, whereas generic producers focus on manufacturing scale and channel optimization.

Based on Drug Class, the market is studied across Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists. The Dopamine Antagonists is further studied across Cisapride, Domperidone, and Metoclopramide, where safety profiles and regulatory legacies govern prescribing limitations and monitoring requirements. The Motilin Receptor Agonists is further studied across Azithromycin and Erythromycin, which offer prokinetic properties but raise concerns about antimicrobial stewardship and long-term tolerability. The Serotonin Receptor Agonists is further studied across Granisetron and Ondansetron, which are primarily utilized for symptom control in specific care settings and may be repurposed or reformulated to enhance delivery. Differentiation across these classes is shaped not only by mechanism of action but also by demonstrable effects on patient-relevant endpoints, regulatory labeling, and long-term safety evidence.

Based on Route Of Administration, the market is studied across Injectable, Oral, and Transdermal approaches, each presenting distinct development and commercialization considerations. Injectable options can offer rapid onset and consistent pharmacokinetics but require clinical settings for administration and introduce cold-chain and device complexities. Oral formulations remain the most practicable for chronic outpatient management, yet they face bioavailability and tolerability constraints that drive reformulation efforts. Transdermal delivery presents an avenue for steady-state exposure and improved adherence but requires investment in device compatibility and robust skin tolerability data.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and channel selection influences reimbursement complexity, patient access pathways, and the economics of specialty versus commodity products. Hospital pharmacies often manage inpatient and acute therapeutic needs and may drive early adoption of novel therapies supported by hospital formularies and therapeutic committees. Online pharmacies have emerged as critical access points for chronic management, where convenience and continuity of supply are weighed against regulatory controls and quality assurance. Retail pharmacies remain central to community-based dispensing and play a pivotal role in patient counseling and adherence support.

Based on End User, the market is studied across Clinics, Home Care Settings, and Hospitals, each shaping the clinical use case and service model for gastroparesis therapies. Clinics frequently manage ambulatory patients requiring ongoing symptomatic management and titration, whereas home care settings demand simplified administration, adherence-support solutions, and remote monitoring capabilities. Hospitals manage acute presentations and complex comorbidities and often influence adoption through institutional protocols and multidisciplinary care pathways. Understanding these segmentation layers helps stakeholders align clinical evidence, pricing strategies, and distribution mechanisms to the distinct needs of each subgroup, thereby informing targeted development and commercialization plans.

A strategic regional analysis illuminating how Americas, Europe, Middle East & Africa, and Asia-Pacific differences impact access, regulation, and commercialization of gastroparesis treatments

Regional dynamics exert a pronounced influence on access pathways, regulatory expectations, and commercial models across the gastroparesis space. In the Americas, incentives for innovation coexist with intense payer scrutiny and diverse reimbursement landscapes that drive differentiated go-to-market tactics and value demonstration requirements. Clinical practice variation across the Americas also shapes formulary selection and the relative uptake of novel versus established agents, while supply chain resilience remains a central operational priority.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous payer systems necessitate adaptive market entry strategies that account for localized pricing negotiations, health technology assessment processes, and varying levels of specialist availability. Countries within this expansive region may prioritize different evidence standards or access pathways, creating opportunities for targeted demonstration projects and early-access agreements. In Asia-Pacific, dynamic growth in healthcare infrastructure, expanding specialty care capacity, and rising patient awareness combine to present both opportunity and complexity. Policymakers and providers in Asia-Pacific are increasingly receptive to models that enhance outpatient management and remote-care delivery, which supports the adoption of oral and transdermal innovations. Across all regions, strategic emphasis on supply chain redundancy, regulatory alignment, and evidence generation tailored to local decision-making frameworks is essential for sustained success.

An incisive corporate overview describing how innovation, alliances, and operational resilience are redefining competitive strategies among gastroparesis drug developers

Company-level behavior in the gastroparesis domain reflects a balance between innovation, lifecycle management, and operational efficiency. Innovator firms continue to invest in targeted mechanisms that promise improved efficacy or tolerability, often coupling clinical development with biomarker strategies and patient-reported outcome measures to substantiate differentiated value. At the same time, specialty and generics manufacturers deploy cost and supply advantages to capture clinical segments where established products remain clinically acceptable.

Strategic alliances-spanning licensing, codevelopment, and contract manufacturing-have become common as firms seek to accelerate time-to-market while controlling development cost and complexity. Firms with integrated manufacturing footprints or strong partnerships with contract organizations are better positioned to absorb trade-related disruptions or to pursue regional production. Additionally, companies are increasingly investing in digital therapeutics adjuncts, remote monitoring, and adherence platforms that complement pharmacologic therapy and provide richer real-world evidence. Collectively, these company-level strategies indicate a pragmatic shift toward collaborative, patient-focused, and operationally resilient business models that sustain long-term competitive advantage.

Practical and prioritized recommendations for industry leaders to strengthen evidence generation, supply resilience, and value-based adoption for gastroparesis therapies

Leaders seeking to secure advantage in gastroparesis therapeutics should prioritize evidence frameworks that demonstrate patient-centered outcomes and real-world effectiveness. Early investment in patient-reported outcome measures, long-term safety registries, and pragmatic trial designs will strengthen value propositions for payers and providers and support differentiated positioning versus incumbent therapies. Strategic collaboration with clinicians and patient advocacy networks can accelerate meaningful endpoint selection and uptake while enriching post-launch data capture.

Operationally, companies should diversify supply chains and evaluate selective nearshoring or regional manufacturing options to mitigate tariff sensitivity and procurement disruption. Investing in digital adherence tools and companion care models will increase the stickiness of therapies delivered in home care and outpatient settings, and these adjuncts can be leveraged to generate ongoing real-world evidence. Finally, pricing strategies must be aligned with demonstrated clinical value, with alternative contracting models considered where outcomes can be reliably measured and validated. Taken together, these measures enable firms to balance access, affordability, and innovation in a rapidly evolving therapeutic and policy landscape.

A transparent and rigorous methodological summary describing how secondary research and targeted primary interviews were triangulated to produce validated insights for stakeholders

The research methodology underpinning this analysis combined systematic secondary research with targeted primary data collection to ensure both breadth and depth of evidence. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and publicly available corporate disclosures, which were synthesized to map therapeutic mechanisms, safety profiles, and regulatory precedents. This foundation was augmented by primary interviews with clinical specialists, supply chain executives, and reimbursement experts to capture real-time perspectives on access barriers, prescribing behavior, and procurement dynamics.

Data synthesis followed a triangulation process to reconcile divergent perspectives and to validate trends across independent sources. Qualitative insights were coded thematically to identify recurring strategic imperatives and operational constraints, while cross-regional comparisons highlighted contextual differences relevant to market entry and commercialization. Limitations include variability in regional data transparency and the evolving nature of trade policy and clinical evidence, which were explicitly accounted for through sensitivity checks and stakeholder validation sessions. The methodology thus balances rigor and pragmatism, delivering actionable intelligence grounded in multi-stakeholder evidence.

A clear and strategic conclusion that synthesizes clinical promise, commercial imperatives, and operational resilience required for successful gastroparesis program execution

In sum, the gastroparesis therapeutic environment is at an inflection point where scientific progress, policy shifts, and operational realities converge to redefine value creation. Advances in targeted pharmacology and delivery technologies offer genuine promise for improved patient outcomes, yet clinical adoption will depend on compelling evidence, payer alignment, and practical administration models that meet the needs of ambulatory and home care settings. Simultaneously, macro-level pressures such as tariffs and supply chain fragility underscore the importance of resilience and strategic sourcing in maintaining patient access and commercial viability.

The path forward requires integrated strategies that couple robust evidence generation with pragmatic operational planning. Firms that align clinical differentiation with resilient manufacturing, flexible distribution models, and outcome-focused contracting will be best positioned to create sustainable impact for patients and stakeholders alike. The insights compiled here provide a strategic foundation for leaders to refine development priorities, optimize commercial paths, and mitigate policy and supply risks as they pursue durable therapeutic and business outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroparesis Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generics

9. Gastroparesis Drugs Market, by Drug Class

  • 9.1. Dopamine Antagonists
    • 9.1.1. Cisapride
    • 9.1.2. Domperidone
    • 9.1.3. Metoclopramide
  • 9.2. Motilin Receptor Agonists
    • 9.2.1. Azithromycin
    • 9.2.2. Erythromycin
  • 9.3. Serotonin Receptor Agonists
    • 9.3.1. Granisetron
    • 9.3.2. Ondansetron

10. Gastroparesis Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Gastroparesis Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Gastroparesis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Gastroparesis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastroparesis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastroparesis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastroparesis Drugs Market

17. China Gastroparesis Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amneal Pharmaceuticals, Inc.
  • 18.8. ANI Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Atlantic Healthcare PLC
  • 18.11. Bausch Health Companies Inc.
  • 18.12. Bristol-Myers Squibb Company
  • 18.13. Cadila Pharmaceuticals Limited
  • 18.14. Cairn Diagnostics
  • 18.15. Evoke Pharma, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Kyowa Kirin International plc
  • 18.19. Lupin Limited
  • 18.20. Medtronic PLC
  • 18.21. Neurogastrx, Inc.
  • 18.22. Novartis AG
  • 18.23. Pfizer, Inc.
  • 18.24. Processa Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Theravance Biopharma
  • 18.28. Vanda Pharmaceuticals Inc.
  • 18.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)